Solu Therapeutics

Solu Therapeutics is a precision-medicine focused company developing therapeutics to eliminate disease-driving cells.

[Solu Therapeutics @Solu_Tx]

As understanding of cancer biology continues to evolve, so does the need for more targeted approaches across oncology. At Solu Therapeutics, we’re advancing research through our CyTAC™ platform to selectively target disease-driving cells: https://t.co/JvA5AEUSGT

[Solu Therapeutics @Solu_Tx]

During #NationalCancerResearchMonth, we’re proud to spotlight @BloodCancerUtd and its Therapeutic Accelerator Program (TAP), bringing together researchers, advocates, and industry to advance blood cancer research.

[Solu Therapeutics @Solu_Tx]

We are proud to announce that STX-0712, our Phase 1 CCR2-CyTAC™ program in development for patients with resistant/refractory #CMML, has received FDA Fast Track designation. For more information, see our press release: https://t.co/pysnLQPTSo

[Solu Therapeutics @Solu_Tx]

Reaching drug targets beyond traditional approaches requires new thinking. Our CyTAC™ platform combines small molecules and antibodies to selectively target disease-driving cells and explore high-value targets.

[Solu Therapeutics @Solu_Tx]

Next week, our team will be at #ASCO26 in Chicago connecting with the global #oncology community and sharing more about our ongoing work. If you’re attending @ASCO, reach out here: https://t.co/uhJzpMTJgk

[Solu Therapeutics @Solu_Tx]

Proudly celebrating three years of Solu! Over three years, we’ve advanced new approaches across #oncology and #immunology through our proprietary CyTAC™ platform, including work in #CMML, #AML, prostate cancer, and inflammatory disease. We are excited for what’s ahead.

[Solu Therapeutics @Solu_Tx]

According to @AmericanCancer, ~333k new prostate cancer cases are expected in the U.S. in 2026. At Solu, we’re advancing research through our CyTAC™ platform, exploring bispecific approaches to selectively target prostate cancer cells. #NationalCancerResearchMonth

[Solu Therapeutics @Solu_Tx]

During #NationalCancerResearchMonth, we recognize the collaboration driving progress in oncology. At Solu, we’re advancing research through our CyTAC™ platform across #CMML, #AML, and prostate cancer—working toward new possibilities for patients: https://t.co/L1sWaQMQYt

[Solu Therapeutics @Solu_Tx]

~44% of cancer deaths in the U.S. are linked to modifiable risk factors (@AmericanCancer), underscoring the importance of prevention and early detection. We’re advancing CyTAC™ approaches in #oncology, focused on #CMML, #AML and prostate cancer. https://t.co/n5d3oVWdUm

[Solu Therapeutics @Solu_Tx]

On #AdministrativeProfessionalsDay, we’re recognizing Sara Vinal, the Sr. Executive Assistant and Office Manager behind the scenes who keeps everything moving at Solu Therapeutics. Thank you for all you do, we’re grateful for you!

[Solu Therapeutics @Solu_Tx]

This weekend, we’re heading to San Diego for #AACR26 to connect with the global #oncology research community. Our VP, Chemistry Jeremy Duvall will be on site to engage with fellow scientists and discuss our ongoing work in #CMML, #AML and prostate cancer.

[Solu Therapeutics @Solu_Tx]

Later this week ahead of #AACR26, our CEO Phil Vickers will be in San Diego for the AACR Oncology Industry Partnering Event: From Cancer Discoveries to Patients, presenting and connecting with #oncology partners. Schedule a meeting: https://t.co/uhJzpMTJgk

[Solu Therapeutics @Solu_Tx]

This week, the team took a break from the day-to-day to catch the Red Sox take on the Brewers at Fenway. Always a great time bringing everyone together and celebrating our Boston roots.

[Solu Therapeutics @Solu_Tx]

On #WorldHealthDay, we #StandWithScience alongside @WHO. We’re committed to advancing approaches that address areas of unmet need across #oncology and #immunology. We believe trust in science is essential to building a healthier future for patients: https://t.co/qtuiTAVDT3

[Solu Therapeutics @Solu_Tx]

As we continue celebrating #WomensHistoryMonth, we’re proud to spotlight Marissa Timothy, VP and Head of Clinical Operations, and her contributions to Solu! We are grateful for her leadership, expertise, and the example she sets for the next generation of #WomenInSTEM.

[Solu Therapeutics @Solu_Tx]

At Solu, we’re advancing #immunology and #inflammation research with approaches designed to eliminate cells that contribute to disease. Our preclinical pipeline includes a CyTAC™ molecule targeting a marker selectively expressed on mast cells. https://t.co/yOaO7NqbAV

[Solu Therapeutics @Solu_Tx]

Next week, our CBO Michael Boretti will represent Solu at #BIOEuropeSpring in Lisbon, connecting with global #LifeSciences and #DrugDiscovery leaders to discuss our CyTAC™ platform and research programs. Schedule a meeting: https://t.co/uhJzpMTJgk

[Solu Therapeutics @Solu_Tx]

For #WomensHistoryMonth, we recognize Dr. Miriam Merad for her contributions to understanding the role of myeloid cells in cancer and #inflammation. Her research has advanced insight into how macrophages and monocytes regulate immune responses.
https://t.co/uXhL33qIkN

[Solu Therapeutics @Solu_Tx]

Our #immunology research includes a preclinical CyTAC™ investigational molecule designed to target monocytes implicated in certain inflammatory diseases. Our work is focused on selectively eliminating cells known to drive certain diseases. https://t.co/yOaO7NqbAV

[Solu Therapeutics @Solu_Tx]

Across research, strategy, and operations, the women of Solu contribute meaningfully to work in #oncology and #immunology, strengthening our science and focus on creating new possibilities for patients. We’re grateful for their impact and commitment. #InternationalWomensDay